Search Results Search Sort by RelevanceMost Recent State of the Art and Science Nov 2015 The Challenge of Understanding Health Care Costs and Charges Vineet Arora, MD, MAPP, Christopher Moriates, MD, and Neel Shah, MD, MPP The price transparency movement seeks to make actual medical costs clear to patients and clinicians. AMA J Ethics. 2015;17(11):1046-1052. doi: 10.1001/journalofethics.2015.17.11.stas1-1511. State of the Art and Science Jan 2021 How Should We Regard Information Gathered in Nazi Experiments? Arthur L. Caplan, PhD Immorally acquired information, from Nazi experimentation or other sources, infects the body of scientific and biomedical knowledge. AMA J Ethics. 2021;23(1):E55-58. doi: 10.1001/amajethics.2021.55. State of the Art and Science Mar 2021 Piloting and Scaling a Good Health Equity Evidence Base From Big Data Stephen Lockhart, MD, PhD One health system’s development and validation of inequity measures across patient groups demonstrates an approach that could be nationally scalable. AMA J Ethics. 2021;23(3):E252-257. doi: 10.1001/amajethics.2021.252. State of the Art and Science Nov 2017 How Should Organizations Promote Equitable Distribution of Benefits from Technological Innovation in Health Care? Satish Nambisan, PhD and Priya Nambisan, PhD Fair distribution demands new strategies for engaging patients in co-creation. AMA J Ethics. 2017;19(11):1106-1115. doi: 10.1001/journalofethics.2017.19.11.stas1-1711. State of the Art and Science Nov 2017 Why Aren’t Our Digital Solutions Working for Everyone? Brian Van Winkle, MBA, Neil Carpenter, MBA, and Mauro Moscucci, MD, MBA To fairly distribute the benefits of digital technologies, clinicians will need to be incentivized to adopt technologies that target the underserved. AMA J Ethics. 2017;19(11):1116-1124. doi: 10.1001/journalofethics.2017.19.11.stas2-1711. State of the Art and Science May 2021 What We Know About Long-acting Injectable Antipsychotics Can Help Innovate HIV Care Olivia S. Kates, MD Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics. AMA J Ethics. 2021;23(5):E405-409. doi: 10.1001/amajethics.2021.405. State of the Art and Science Aug 2021 How Economic Decision Modeling Can Facilitate Health Equity Jeffrey S. Hoch, PhD, Logan Trenaman, PhD, Shannon M. Hearney, MPH, and Carolyn S. Dewa, PhD, MPH Modeling how technology assessment fits into cost-effectiveness frameworks can broaden the range of options for improving health equity. AMA J Ethics. 2021;23(8):E624-630. doi: 10.1001/amajethics.2021.624. State of the Art and Science Oct 2020 Using OCAP and IQ as Frameworks to Address a History of Trauma in Indigenous Health Research Angela Mashford-Pringle, PhD and Kira Pavagadhi, MPH Researchers and scholars should co-develop research with Indigenous peoples to ensure respect for culture, language, and ways of knowing. AMA J Ethics. 2020;22(10):E868-873. doi: 10.1001/amajethics.2020.868. State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645. State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654. Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
State of the Art and Science Nov 2015 The Challenge of Understanding Health Care Costs and Charges Vineet Arora, MD, MAPP, Christopher Moriates, MD, and Neel Shah, MD, MPP The price transparency movement seeks to make actual medical costs clear to patients and clinicians. AMA J Ethics. 2015;17(11):1046-1052. doi: 10.1001/journalofethics.2015.17.11.stas1-1511.
State of the Art and Science Jan 2021 How Should We Regard Information Gathered in Nazi Experiments? Arthur L. Caplan, PhD Immorally acquired information, from Nazi experimentation or other sources, infects the body of scientific and biomedical knowledge. AMA J Ethics. 2021;23(1):E55-58. doi: 10.1001/amajethics.2021.55.
State of the Art and Science Mar 2021 Piloting and Scaling a Good Health Equity Evidence Base From Big Data Stephen Lockhart, MD, PhD One health system’s development and validation of inequity measures across patient groups demonstrates an approach that could be nationally scalable. AMA J Ethics. 2021;23(3):E252-257. doi: 10.1001/amajethics.2021.252.
State of the Art and Science Nov 2017 How Should Organizations Promote Equitable Distribution of Benefits from Technological Innovation in Health Care? Satish Nambisan, PhD and Priya Nambisan, PhD Fair distribution demands new strategies for engaging patients in co-creation. AMA J Ethics. 2017;19(11):1106-1115. doi: 10.1001/journalofethics.2017.19.11.stas1-1711.
State of the Art and Science Nov 2017 Why Aren’t Our Digital Solutions Working for Everyone? Brian Van Winkle, MBA, Neil Carpenter, MBA, and Mauro Moscucci, MD, MBA To fairly distribute the benefits of digital technologies, clinicians will need to be incentivized to adopt technologies that target the underserved. AMA J Ethics. 2017;19(11):1116-1124. doi: 10.1001/journalofethics.2017.19.11.stas2-1711.
State of the Art and Science May 2021 What We Know About Long-acting Injectable Antipsychotics Can Help Innovate HIV Care Olivia S. Kates, MD Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics. AMA J Ethics. 2021;23(5):E405-409. doi: 10.1001/amajethics.2021.405.
State of the Art and Science Aug 2021 How Economic Decision Modeling Can Facilitate Health Equity Jeffrey S. Hoch, PhD, Logan Trenaman, PhD, Shannon M. Hearney, MPH, and Carolyn S. Dewa, PhD, MPH Modeling how technology assessment fits into cost-effectiveness frameworks can broaden the range of options for improving health equity. AMA J Ethics. 2021;23(8):E624-630. doi: 10.1001/amajethics.2021.624.
State of the Art and Science Oct 2020 Using OCAP and IQ as Frameworks to Address a History of Trauma in Indigenous Health Research Angela Mashford-Pringle, PhD and Kira Pavagadhi, MPH Researchers and scholars should co-develop research with Indigenous peoples to ensure respect for culture, language, and ways of knowing. AMA J Ethics. 2020;22(10):E868-873. doi: 10.1001/amajethics.2020.868.
State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645.
State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654.